{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-000218","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.376877+00:00","generated_at":"2026-06-20T20:24:15.241056+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reviva reports 40% enrollment in Phase 3 schizophrenia trial; top-line data expected mid-2023","bullets":["About 40% of patients treated in pivotal Phase 3 RECOVER trial of brilaroxazine; no treatment-related SAEs.","Top-line data from Phase 3 trial expected mid-2023; NDA submission planned if positive, potential commercial launch in 2025.","Completed DDI study for brilaroxazine; results indicate advantage over other antipsychotics regarding drug interactions.","Raised $8.5M in September 2022 from registered direct offering and private placement; improved financial position.","Exploring non-dilutive financing and partnerships to expand brilaroxazine into bipolar, MDD, ADHD, PAH, IPF; combined market >$70B."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-000218","json":"https://secwatch.observer/filing/0001437749-23-000218.json","markdown":"https://secwatch.observer/filing/0001437749-23-000218.md","text":"https://secwatch.observer/filing/0001437749-23-000218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923000218/0001437749-23-000218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923000218/rvph20230102_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:24:15.241056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}